A group of academics claim the president of EcoHealth Alliance has misled the public amid Covid origins investigations.
Should work done on coronaviruses in Wuhan, China, be considered “gain-of-function” research? Opinions differ.
The U.S.’s top infectious disease specialist describes a new Biden administration program to develop and test antivirals—and what he’s most worried about as the nation reopens
With the risks of drug development prohibitive, repurposed or repositioned medicines appear the best hope against long-COVID, a condition that still raises many unanswered questions.
More than a year into the SARS-CoV-2 pandemic, some scientists say the possibility of a lab leak never got a fair look.
A treatment from World War I is making a comeback in the struggle to beat deadly multidrug-resistant infections